attana - sensor technologies

Blocking tumor cell growth

Professor Roland Kontermann and his team at the Institute of Cell Biology and Immunology at University of Stuttgart have recently published another article in mAbs demonstrating that a novel human antibody, IgG 3-43, blocks tumor cell growth both in vitro and in vivo.

Stockholm, June 4, 2017 – Professor Roland Kontermann and his group have recently published an article in mAbs, with the title, Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Professor Kontermann's research interests focus on the development of recombinant antibodies with improved biological and pharmacokinetic properties and targeted nanoparticulate carrier systems for cancer therapy.

In this latest article it is demonstrated that a novel human antibody, IgG 3-43, blocks tumor cell growth both in vitro and in vivo, by efficiently inhibiting the activation of HER3 (human epidermal growth factor receptor).

An abstract of the publication can be found here.

To learn more about Attana contract research services and our label free cell-based biosensors, please visit www.attana.com or contact our sales department, sales@attana.com.

About Attana:

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. www.attana.com/about-us/attana-movie-2015/